Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.35 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.92 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.34 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124540 | 0.96 | GRM2 (1.00) | GRM2HTR2CPHGDHSTAT3ALDH1A1 | |
| SCHEMBL1003316 | 0.88 | GRM2 (0.85) | GRM2PHGDHSTAT3ALDH1A1PPARG | |
| SCHEMBL2023554 | 0.88 | GRM2 (0.84) | GRM2STAT3ALDH1A1PPARGPPARD | |
| SCHEMBL1000992 | 0.85 | GRM2 (0.81) | GRM2PHGDHSTAT3ALDH1A1PPARG | |
| SCHEMBL2123824 | 0.84 | GRM2 (0.78) | GRM2ALDH1A1KCNH2 | |
| SCHEMBL30789127 | 0.84 | GRM2 (0.78) | GRM2ALDH1A1KCNH2 | |
| SCHEMBL2022166 | 0.84 | GRM2 (0.78) | GRM2HTR2CALDH1A1PPARGPPARD | |
| SCHEMBL1005072 | 0.84 | GRM2 (0.76) | GRM2PHGDHSTAT3ALDH1A1SCN5A | |
| SCHEMBL2022840 | 0.84 | GRM2 (0.75) | GRM2HTR2CALDH1A1PPARGPPARD | |
| SCHEMBL16673472 | 0.83 | GRM2 (0.74) | GRM2PHGDHSTAT3ALDH1A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130237548-A1 | INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT | ASTRAZENECA AB (SE) | 2013-09-12 | — | — | US | claimed |
| EP-2563782-A1 | POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR | AstraZeneca AB (SE) | 2013-03-06 | — | — | EP | claimed |
| WO-2011136723-A1 | POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR | ASTRAZENECA AB (SE) | 2011-11-03 | — | — | WO | claimed |
| US-20240050427-A1 | TREATMENTS FOR OBSESSIVE COMPULSIVE DISORDER | SIRGARTAN HOLDINGS LTD (GB) | 2024-02-15 | — | — | US | disclosed |
| WO-2024028611-A1 | OXADIAZOLE COMPOUNDS FOR USE IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER | SIRGARTAN HOLDINGS LTD (GB) | 2024-02-08 | — | — | WO | disclosed |
| US-20130237548-A1 | INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT | ASTRAZENECA AB (SE) | 2013-09-12 | — | — | US | disclosed |
| US-20130237548-A1 | INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT | ASTRAZENECA AB (SE) | 2013-09-12 | — | — | US | disclosed |
| EP-2563782-A1 | POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR | AstraZeneca AB (SE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2563782-A1 | POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR | AstraZeneca AB (SE) | 2013-03-06 | — | — | EP | disclosed |
| CN-102858766-A | Polymorphs of a metabotropic glutamate receptor positive allosteric modulator | ASTRAZENECA AB | 2013-01-02 | — | — | CN | disclosed |
| WO-2011136723-A1 | POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR | ASTRAZENECA AB (SE) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011136723-A1 | POLYMORPHS OF A METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATOR | ASTRAZENECA AB (SE) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050427-A1 | TREATMENTS FOR OBSESSIVE COMPULSIVE DISORDER | HCRTR1, HCRTR2, TAAR5 | HTR2C 7/4885GRIN2B 94/4885GRM2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.